Suzanne Cadden has been named vice president of Regulatory Affairs & Quality at ImmunoGen. Ms. Cadden will be responsible for establishing – in conjunction with the chief medical officer – the registration strategy for the company’s product candidates, for directing the development of regulatory submissions prepared by ImmunoGen in support of its own programs and those of its partners, and for managing the company’s manufacturing-associated quality functions. Ms. Cadden reports to Daniel Junius, ImmunoGen’s president and chief executive officer.

“Suzanne brings to ImmunoGen extensive regulatory experience – both with the FDA and with international agencies – that we expect will be highly beneficial to our advancement of our own product candidates and our support of partner programs,” commented Mr. Junius. “Further, I believe that as a member of our senior management team, Suzanne will play an important role in our taking ImmunoGen to the next level.”

Ms. Cadden brings to ImmunoGen over 20 years of experience gained at both pharmaceutical and biotechnology companies. Prior to joining ImmunoGen, she was vice president of Regulatory Affairs & Clinical Development at Sierra Neuropharmaceuticals. Before that, she was vice president of Regulatory Affairs & Clinical Operations at ActivBiotics and held senior positions at Transition Therapeutics, LORUS Therapeutics, Glaxo Wellcome and CIBA, Canada.